Literature DB >> 29990710

Derivation and molecular characterization of pancreatic differentiated MODY1-iPSCs.

Carmel Braverman-Gross1, Neta Nudel1, Daniel Ronen1, Nicola L Beer2, Mark I McCarthy2, Nissim Benvenisty3.   

Abstract

Maturity onset diabetes of the young (MODY) is a hereditary form of diabetes mellitus presenting at childhood or adolescence, which eventually leads to pancreatic β-cells dysfunction. The underlying genetic basis of MODY disorders is haploinsufficiency, where loss-of-function mutations in a single allele cause the diabetic phenotype in heterozygous patients. MODY1 is a type of MODY disorder resulting from a mutation in the transcription factor hepatocyte nuclear factor 4 alpha (HNF4α). In order to establish a human based model to study MODY1, we generated patient-derived induced pluripotent stem cells (iPSCs). Differentiation of these pluripotent cells towards the pancreatic lineage enabled to evaluate the effects of the MODY1 mutation and its impact on endodermal and pancreatic cells. Analyzing the gene expression profiles of differentiated MODY1 cells, revealed the outcome of HNF4α haploinsufficiency on its targets. This molecular analysis suggests that the differential expression of HNF4α target genes in MODY1 is affected by the number of HNF4α binding sites, their distance from the transcription start site, and the number of other transcription factor binding sites. These features may help explain the molecular manifestations of haploinsufficiency in MODY1 disease.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Binding sites; Differentiation; HNF4α; MODY1; Transcription factor; iPS cells

Mesh:

Year:  2018        PMID: 29990710     DOI: 10.1016/j.scr.2018.06.013

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  15 in total

Review 1.  Toward Precision Medicine with Human Pluripotent Stem Cells for Diabetes.

Authors:  Bushra Memon; Essam M Abdelalim
Journal:  Stem Cells Transl Med       Date:  2022-07-20       Impact factor: 7.655

Review 2.  Who Will Win: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells for β Cell Replacement and Diabetes Disease Modeling?

Authors:  Elena F Jacobson; Emmanuel S Tzanakakis
Journal:  Curr Diab Rep       Date:  2018-10-20       Impact factor: 4.810

Review 3.  Modeling different types of diabetes using human pluripotent stem cells.

Authors:  Essam M Abdelalim
Journal:  Cell Mol Life Sci       Date:  2020-11-26       Impact factor: 9.261

Review 4.  Modeling Type 1 Diabetes Using Pluripotent Stem Cell Technology.

Authors:  Kriti Joshi; Fergus Cameron; Swasti Tiwari; Stuart I Mannering; Andrew G Elefanty; Edouard G Stanley
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-01       Impact factor: 5.555

Review 5.  The Human Islet: Mini-Organ With Mega-Impact.

Authors:  John T Walker; Diane C Saunders; Marcela Brissova; Alvin C Powers
Journal:  Endocr Rev       Date:  2021-09-28       Impact factor: 25.261

6.  Expression of mutant mRNA and protein in pancreatic cells derived from MODY3- iPS cells.

Authors:  Shigeharu G Yabe; Junko Nishida; Satsuki Fukuda; Fujie Takeda; Kiyoko Nasiro; Kazuki Yasuda; Naoko Iwasaki; Hitoshi Okochi
Journal:  PLoS One       Date:  2019-05-30       Impact factor: 3.240

Review 7.  Recent progress in pancreatic islet cell therapy.

Authors:  Erinn Zixuan Sim; Nobuaki Shiraki; Shoen Kume
Journal:  Inflamm Regen       Date:  2021-01-05

Review 8.  Monogenic Diabetes Modeling: In Vitro Pancreatic Differentiation From Human Pluripotent Stem Cells Gains Momentum.

Authors:  Juan Ignacio Burgos; Ludovic Vallier; Santiago A Rodríguez-Seguí
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-06       Impact factor: 5.555

Review 9.  Human Pluripotent Stem Cells Go Diabetic: A Glimpse on Monogenic Variants.

Authors:  Sandra Heller; Michael Karl Melzer; Ninel Azoitei; Cécile Julier; Alexander Kleger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-17       Impact factor: 5.555

Review 10.  Genome Editing Human Pluripotent Stem Cells to Model β-Cell Disease and Unmask Novel Genetic Modifiers.

Authors:  Matthew N George; Karla F Leavens; Paul Gadue
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-02       Impact factor: 6.055

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.